NeoGenomics reports Q3 EPS (14c), consensus 1c

Reports Q3 revenue $168M, consensus $167.01M. Adjusted EBITDA improves 305%; ; Increasing FY Guidance to $37-$40M…”We delivered a strong third quarter, again growing revenue by double digits and increasing adjusted EBITDA by over 300%, all while serving a record number of patients,” said Chris Smith, Chief Executive Officer of NeoGenomics (NEO). “Our results demonstrate our teammates’ commitment to executing on our strategic priorities. This disciplined approach has enabled us to increase our adjusted EBITDA expectations for the year while continuing to position the Company for long term, sustainable growth.”